PharmGen Science, Inc.
KRX:004720.KS
4815 (KRW) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 166,778.826 | 150,930.715 | 109,866.067 | 96,614.31 | 95,137.669 | 89,101.64 | 79,894.497 | 71,545.613 | 60,405.445 | 44,203.012 | 38,971.053 | 30,291.621 | 27,911.913 | 43,926.893 | 48,740.944 | 77,680.145 | 78,559.32 |
Cost of Revenue
| 70,579.798 | 69,628.645 | 49,063.066 | 43,015.223 | 44,737.88 | 42,899.758 | 38,642.372 | 31,568.982 | 28,048.395 | 20,323.27 | 17,017.802 | 14,002.458 | 12,628.059 | 14,790.021 | 17,646.314 | 47,241.737 | 50,398.67 |
Gross Profit
| 96,199.027 | 81,302.07 | 60,803 | 53,599.088 | 50,399.788 | 46,201.882 | 41,252.125 | 39,976.631 | 32,357.05 | 23,879.742 | 21,953.25 | 16,289.163 | 15,283.855 | 29,136.872 | 31,094.63 | 30,438.408 | 28,160.65 |
Gross Profit Ratio
| 0.577 | 0.539 | 0.553 | 0.555 | 0.53 | 0.519 | 0.516 | 0.559 | 0.536 | 0.54 | 0.563 | 0.538 | 0.548 | 0.663 | 0.638 | 0.392 | 0.358 |
Reseach & Development Expenses
| 5,118.144 | 2,886.438 | 2,269.549 | 1,114.873 | 886.295 | 1,239.602 | 985.832 | 694.006 | 528.655 | 437.243 | 422.955 | 409.27 | 401.356 | 725.786 | 655.787 | 624.64 | 432.071 |
General & Administrative Expenses
| 7,467.112 | 7,219.929 | 6,331.948 | 5,431.056 | 5,496.105 | 4,894.814 | 4,869.912 | 4,775.768 | 4,315.767 | 5,257.447 | 4,416.076 | 3,025.747 | 2,914.859 | 7,249.882 | 7,893.924 | 6,260.221 | 5,942.429 |
Selling & Marketing Expenses
| 54,394.988 | 40,602.915 | 32,640.53 | 25,726.456 | 22,083.857 | 15,772.979 | 12,015.657 | 12,169.689 | 8,958.257 | 9,649.048 | 8,003.162 | 5,794.592 | 5,254.803 | 7,586.233 | 5,515.392 | 2,965.661 | 2,468.762 |
SG&A
| 86,865.295 | 47,822.844 | 38,972.478 | 31,157.512 | 27,579.962 | 20,667.793 | 16,885.569 | 16,945.457 | 13,274.024 | 14,906.495 | 12,419.238 | 8,820.339 | 8,169.662 | 14,836.115 | 13,409.316 | 9,225.882 | 8,411.191 |
Other Expenses
| -206.934 | 23,110.424 | 24,498.893 | 21,776.608 | 20,736.211 | -227.029 | -363.643 | -129.64 | -1,833.064 | -211.72 | -123.452 | 810.62 | 8,787.129 | -2,546.851 | -631.094 | 40.29 | 88.656 |
Operating Expenses
| 87,072.229 | 73,819.706 | 65,740.92 | 54,048.993 | 49,202.468 | 41,215.95 | 35,241.181 | 35,141.452 | 27,832.744 | 27,489.706 | 25,384.166 | 21,320.204 | 17,358.147 | 26,215.115 | 28,096.939 | 26,626.749 | 25,494.86 |
Operating Income
| 9,126.798 | 95,027.305 | 42,494.855 | 14,224.606 | 1,187.32 | 4,985.932 | 6,010.943 | 4,835.179 | 4,524.306 | -3,609.964 | -3,430.916 | -5,031.041 | -3,898.392 | 2,921.76 | 2,997.693 | 3,811.656 | 2,665.79 |
Operating Income Ratio
| 0.055 | 0.63 | 0.387 | 0.147 | 0.012 | 0.056 | 0.075 | 0.068 | 0.075 | -0.082 | -0.088 | -0.166 | -0.14 | 0.067 | 0.062 | 0.049 | 0.034 |
Total Other Income Expenses Net
| 1,123.53 | -5,067.005 | -545.37 | -3,015.316 | -783.142 | -1,093.371 | 68.354 | -333.168 | -2,391.801 | -1,035.243 | -428.811 | -246.647 | -6,615.541 | -4,601.834 | -2,337.009 | -5,863.148 | -1,665.836 |
Income Before Tax
| 10,250.328 | 89,960.3 | 41,949.485 | 11,209.29 | 404.179 | 3,892.561 | 6,079.298 | 4,502.012 | 2,132.505 | -4,645.206 | -3,859.727 | -5,277.688 | -8,689.834 | -1,680.077 | 660.682 | -2,051.489 | 999.954 |
Income Before Tax Ratio
| 0.061 | 0.596 | 0.382 | 0.116 | 0.004 | 0.044 | 0.076 | 0.063 | 0.035 | -0.105 | -0.099 | -0.174 | -0.311 | -0.038 | 0.014 | -0.026 | 0.013 |
Income Tax Expense
| 2,265.007 | 19,902.113 | 9,535.062 | 2,085.232 | 168.183 | -603.116 | 1,645.915 | 1,031.481 | 49.435 | -24.547 | -80.534 | 48.492 | 156.904 | 1,085.558 | 3,159.33 | 9,263.915 | 1,221.788 |
Net Income
| 5,727.239 | 70,059.662 | 32,465.959 | 9,222.178 | 235.996 | 4,467.984 | 4,319.9 | 3,452.136 | 2,067.281 | -4,583.68 | -3,698.557 | -5,231.61 | -8,823.738 | -2,765.635 | -1,946.753 | -11,315.404 | -221.835 |
Net Income Ratio
| 0.034 | 0.464 | 0.296 | 0.095 | 0.002 | 0.05 | 0.054 | 0.048 | 0.034 | -0.104 | -0.095 | -0.173 | -0.316 | -0.063 | -0.04 | -0.146 | -0.003 |
EPS
| 351.99 | 4,498.1 | 2,206.02 | 674.98 | 20.45 | 390.15 | 395 | 364 | 233 | -579 | -468.94 | -740 | -1,397.73 | -452.34 | -358.22 | -2,079.71 | -39.49 |
EPS Diluted
| 306.26 | 3,369.29 | 1,814.33 | 623.34 | 20.45 | 390 | 392 | 358 | 233 | -579 | -468.94 | -740 | -1,397.73 | -452.34 | -358.22 | -2,079.71 | -39.49 |
EBITDA
| 13,373.525 | 98,398.435 | 45,636.791 | 17,187.414 | 3,682.052 | 5,921.747 | 7,267.336 | 5,748.449 | 3,587.705 | -2,798.653 | -2,442.678 | -3,230.362 | -4,337.822 | 769.095 | 4,673.666 | 7,166.745 | 7,477.574 |
EBITDA Ratio
| 0.08 | 0.652 | 0.415 | 0.178 | 0.039 | 0.066 | 0.091 | 0.08 | 0.059 | -0.063 | -0.063 | -0.107 | -0.155 | 0.018 | 0.096 | 0.092 | 0.095 |